Skip to main content
Menu
MorphoSys US
  • EN
  • DE
  • CompanyMorphoSys in a Nutshell
    • CompanyMain Menu
    • Sustainable business modelMain Menu
      • Balanced business model
      • Research and development
    • ManagementMain Menu
      • Executive Committee
      • Supervisory Board
    • SubsidiariesMain Menu
      • MorphoSys US Inc.
    • HistoryMain Menu
    • ContactMain Menu
      • Media and investors
      • Business development
      • Innovation capital
      • Careers
      • Drug safety
  • PipelineThe Therapeutic Pipeline
    • PipelineMain Menu
    • Clinical development expertiseMain Menu
      • Clinical Development
      • Drug Safety
      • Regulatory Affairs
      • Quality Assurance
    • Proprietary portfolioMain Menu
      • Tafasitamab (MOR208)
      • Felzartamab (MOR202)
      • Otilimab (MOR103/GSK3196165)
    • Product on marketMain Menu
      • Monjuvi® (tafasitamab-cxix)
      • Tremfya® (guselkumab)
  • ScienceEngineering the Medicines of Tomorrow
    • ScienceMain Menu
    • Scientific research expertiseMain Menu
      • Discovery, Alliances and Technologies
      • Protein Sciences
      • Preclinical Development
      • Our Technologies
    • Main research areasMain Menu
      • Cancer
      • Immuno-oncology
      • Inflammatory and autoimmune Diseases
      • Antibodies targeting GPCRs
    • External Scientific Advisory Board (SAB)Main Menu
  • PartneringMorphoSys as a Partner
    • PartneringMain Menu
    • Global BD&L and Alliance ManagementMain Menu
      • Business Development & Licensing
      • Alliance Management
    • Partnering opportunitiesMain Menu
      • Early-stage
      • Mid-stage
      • Late-stage
      • Technology
      • Contact
    • Innovation CapitalMain Menu
      • Innovation capital
      • Investment approach
      • Contact
  • Media and investorsInvest in the Medicines of Tomorrow
    • Media and investorsMain Menu
    • Stock informationMain Menu
      • General information
      • Stock charts
      • Share price performance
      • Recent voting rights notifications
      • Analysts
      • ADS
      • Share buy-back
    • Investor & Media informationMain Menu
      • Corporate releases
      • Order form for publications and reports
      • SEC-Filings
      • Ad-hoc releases
      • Statement on Impact of COVID-19
      • Conferences
      • Company Update
      • Pictures
      • Awards & Recognition
    • Financial informationMain Menu
      • Financial guidance
      • Fundamentals
      • Business segments
      • Financial reports
    • MorphoSys eventsMain Menu
      • Company calendar
      • Upcoming conferences
      • Conference Archive
    • Corporate governanceMain Menu
      • Managers’ Transactions
    • Annual General MeetingMain Menu
  • CareerWorking with us
    • Career at MorphoSysMain Menu
    • Welcome to career at MorphoSysMain Menu
    • MorphoSys as employerMain Menu
    • Your CareerMain Menu
    • Your applicationMain Menu
    • VacanciesMain Menu

You are leaving morphosys.com and will be transferred to the MorphoSys US website which is intended for US residents.

Do you wish to proceed?

Yes No
  • © 2021 Morphosys AG
  • Imprint
  • Terms and Conditions
  • Privacy policy
  • General Terms & Conditions of Purchase
  • Contact

Address
MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Phone: +49 89 899 27-0
Fax: +49 89 899 27-222
E-Mail: info@morphosys.com

  • MorphoSys US Inc.
  • Company
    • Sustainable business modelMain Menu
    • ManagementMain Menu
    • MorphoSys US Inc.Main Menu
  • Pipeline
    • Tafasitamab (MOR208)Main Menu
    • Felzartamab (MOR202)Main Menu
    • Otilimab (MOR103/GSK3196165)Main Menu
  • Media and investors
    • Stock informationMain Menu
    • Investor & Media informationMain Menu
    • Financial informationMain Menu
    • EventsMain Menu
    • Annual general meetingMain Menu
  • Careers
    • VacanciesMain Menu